You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Drugs

The drug library provides access to information on over 100 cancer drugs available for use in Canada.

Displaying Drugs List

33 Items
Other Name(s): Arimidex® (multiple brands available)
Funding:
ODB Limited Use
  • anastrozole - For the treatment of metastatic breast cancer in hormone receptor positive post-menopausal women
  • anastrozole - An alternative to tamoxifen for the adjuvant treatment of postmenopausal women with hormone receptor positive breast cancer
Apr 2016
Other Name(s): Xeloda® (multiple brands available)
Funding:
ODB Limited Use
  • capecitabine - As part of the CAPOX (XELOX) regimen for the first-line and second-line treatment of metastatic colorectal, small bowel or appendiceal adenocarcinomas.
  • capecitabine - For adjuvant treatment of stage 3 or high risk stage 2* colon, small bowel or appendiceal adenocarcinomas in patients who have completed surgery (within three months), who would normally be candidates for adjuvant chemotherapy with 5FU/LV.
  • capecitabine - First-line treatment of patients with metastatic colorectal, small bowel and appendiceal adenocarcinomas in whom combination chemotherapy is not recommended.
  • capecitabine - Treatment of metastatic breast cancer where patients have progressed after prior chemotherapy
  • capecitabine - In combination with trastuzumab and cisplatin for the treatment of patients with HER2-positive metastatic adenocarcinoma of the stomach or gastro-esophageal junction who have not received prior anti-cancer treatment for their metastatic disease
  • capecitabine - Neo-adjuvant treatment of rectal cancer
  • capecitabine - In combination with a platinum-containing product and epirubicin for the treatment of advanced (non-resectable; either locally advanced or metastatic) gastric or gastro-esophageal junction cancer
  • capecitabine - As part of the CAPOX (XELOX) regimen for the treatment of adjuvant stage III and high risk stage II colorectal, small bowel or appendiceal adenocarcinomas.
Dec 2016
Other Name(s): Paraplatin AQ® (multiple brands available)
Aug 2016
Other Name(s): Platinol AQ® (multiple brands available)
Aug 2016
Other Name(s): Procytox® (Baxter)
Funding:
ODB - General Benefit
  • cyclophosphamide - oral tablets
Nov 2017
Other Name(s): Taxotere® (multiple brands available)
Funding:
New Drug Funding Program
  • Docetaxel - Metastatic Castration-Resistant Prostate Cancer
  • Docetaxel - Non-Small Cell Lung Cancer (NSCLC)
  • Docetaxel - Non-Small Cell Lung Cancer (Second or Subsequent Line)
  • Docetaxel - Neoadjuvant treatment for Non-Metastatic Breast Cancer
  • Docetaxel - Metastatic Breast Cancer
  • Docetaxel - Hormone Sensitive Prostate Cancer
  • Trastuzumab with First Line Docetaxel - Metastatic Breast Cancer
  • Docetaxel - CYCLDOCE for Early Operable Breast Cancer
  • Docetaxel - FEC-D or AC-DOCE for Adjuvant Treatment for Breast Cancer
Nov 2017
Other Name(s): Adriamycin PFS® (multiple brands available)
Nov 2017
Other Name(s): Pharmorubicin PFS® (multiple brands available)
Funding:
New Drug Funding Program
  • Epirubicin - Adjuvant Treatment for Breast Cancer
  • Epirubicin - Neoadjuvant Treatment for Non-Metastatic Breast Cancer
Aug 2016
Other Name(s): Halaven® (Eisai)
Funding:
New Drug Funding Program
  • Eribulin - Metastatic or Incurable Locally Advanced - Breast Cancer
Updated
Jan 2018
Other Name(s): Vepesid® (multiple brands available)
Funding:
ODB - General Benefit
  • etoposide - oral capsules
Nov 2017
Other Name(s): Afinitor® (Novartis)
Funding:
Exceptional Access Program
  • everolimus - In combination with exemestane, for the treatment of hormone-receptor positive, HER2 negative advanced breast cancer, in postmenopausal women with ECOG performance status less than or equal to 2 after recurrence or progression following a non-steroidal aromatase inhibitor (NSAI)
  • everolimus - Metastatic renal cell carcinoma, with specific criteria
  • everolimus - For the treatment of unresectable, locally advanced or metastatic, well-differentiated non-functional neuroendocrine tumours (NETs) of GI or lung origin, according to clinical criteria
Dec 2017
Other Name(s): Aromasin® (multiple brands available)
Funding:
ODB Limited Use
  • exemestane - In combination with everolimus, for the treatment of hormone-receptor positive HER2 negative advanced breast cancer, in postmenopausal women with ECOG performance status less than or equal to 2 after recurrence or progression following a non-steroidal aromatase inhibitor (NSAI)
  • exemestane - Hormonal treatment of metastatic breast cancer in hormone receptor positive postmenopausal women who have disease progression following tamoxifen therapy
  • exemestane - Sequential treatment of postmenopausal women with estrogen receptor-positive early breast cancer who have received 2-3 years of initial adjuvant tamoxifen therapy
May 2014